Werewolf Therapeutics, Inc. (HOWL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Werewolf Therapeutics, Inc. (HOWL)
Company Performance

Current Price

as of Oct 16, 2024

$2.06

P/E Ratio

N/A

Market Cap

$90.03M

Description

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Metrics

Overview

  • HQWatertown, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerHOWL
  • Price$2.06+2.49%

Trading Information

  • Market Cap$90.03M
  • Float69.55%
  • Average Daily Volume (1m)141,622
  • Average Daily Volume (3m)162,312
  • EPS-$1.35

Company

  • Revenue$9.28M
  • Rev Growth (1yr)-85.86%
  • Net Income-$17.25M
  • Gross Margin60.28%
  • EBITDA Margin-1,619.07%
  • EBITDA-$18.51M
  • EV$7.57M
  • EV/Revenue0.81
  • P/EN/A
  • P/S9.66
  • P/B0.87
Documents